Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review
Abnormal cellular apoptosis plays a pivotal role in the pathogenesis of Multiple Myeloma
(MM). Over the years, BCL-2, a crucial anti-apoptotic protein, has garnered significant …
(MM). Over the years, BCL-2, a crucial anti-apoptotic protein, has garnered significant …
The role of venetoclax in relapsed/refractory acute myeloid leukemia: past, present, and future directions
Relapsed and/or refractory (R/R) acute myeloid leukemia (AML) is hallmarked by dramatic
prognosis. Treatment remains challenging, with allogeneic hematopoietic stem cell …
prognosis. Treatment remains challenging, with allogeneic hematopoietic stem cell …
Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia
M Aiba, A Shigematsu, T Suzuki, T Miyagishima - Annals of Hematology, 2023 - Springer
Venetoclax (VEN) is now widely used in the treatment of acute myelogenous leukemia
(AML) in elderly patients who are not eligible for intensive remission induction therapy …
(AML) in elderly patients who are not eligible for intensive remission induction therapy …
[HTML][HTML] The growing role of the BH3 mimetic drug Venetoclax in the therapy of acute myeloid leukemia
E Pelosi, G Castelli, U Testa - Mediterranean Journal of …, 2022 - ncbi.nlm.nih.gov
Despite recent progress, acute myeloid leukemia (AML) remains a disease associated with
poor prognosis, particularly in older AML patients unfit to tolerate intensive chemotherapy …
poor prognosis, particularly in older AML patients unfit to tolerate intensive chemotherapy …
Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up
CJ Khouderchah, LL Benitez, BL Marini… - Leukemia & …, 2024 - Taylor & Francis
Venetoclax with hypomethylating agents (HMAs) is an important treatment for patients with
acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. However, there …
acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. However, there …
Pityriasiform drug eruption associated with venetoclax for acute myeloid leukaemia
TJ Liu, EK McMeniman - Anti-Cancer Drugs, 2024 - journals.lww.com
Venetoclax is a targeted antileukaemic therapy that has emerged as the primary treatment of
acute myeloid leukaemia in patients of advanced age or who would otherwise be ineligible …
acute myeloid leukaemia in patients of advanced age or who would otherwise be ineligible …
Modeling normal and malignant hematopoiesis in vitro. To screen for extrinsic regulators and differentiation therapy.
S Hultmark - 2022 - portal.research.lu.se
The incredible thing with blood stem cells, also known as hematopoietic stem cells (HSC), is
that they can restore normal hematopoiesis in patients that need a new blood system. Since …
that they can restore normal hematopoiesis in patients that need a new blood system. Since …
Infection risk and role of antibiotic prophylaxis in acute myeloid leukemia patients receiving lower intensity chemotherapy: A literature review
D Castro - 2024 - mspace.lib.umanitoba.ca
Patients with acute myeloid leukemia (AML) are at high risk for infections due to
chemotherapy-induced neutropenia. AML patients who receive lower dose chemotherapy …
chemotherapy-induced neutropenia. AML patients who receive lower dose chemotherapy …
How do I manage the myelotoxicity of venetoclax and azacitidine in patients with newly diagnosed acute myeloid leukemia?
A Salomon-Perzyński… - Hematology in Clinical …, 2023 - journals.viamedica.pl
The introduction of venetoclax in combination with azacitidine (venAZA) represents a turning
point in the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who …
point in the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who …